CRLComplete Response Letter
Complete Response Letter Glenmark Pharmaceuticals, Inc. (Jun 20, 2019)
FDA's complete response letter contains source-text evidence related to Labeling, packaging, and proprietary name, Safety and adverse events, Facility inspection and CGMP compliance. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Issued
US FDA• RYALTRIS
